*Mycoplasma pneumoniae* – modern data on the structure, molecular biology and epidemiology of the pathogen

A. Edelstein Inna

doi:10.36488/cmac.2023.4.332-349

1. Saraya T. The history of Mycoplasma pneumoniae pneumonia. Front Microbiol. 2016;7:364. DOI: 10.3389/fmicb.2016.00364

2. Gupta R.S., Oren A. Necessity and rationale for the proposed name changes in the classification of Mollicutes species. Reply to: ‘Recommended rejection of the names Malacoplasma gen. nov., Mesomycoplasma gen. nov., Metamycoplasma gen. nov., Metamycoplasmataceae fam. nov. [Gupta, Sawnani, Adeolu, Alnajar and Oren 2018] and all proposed species comb. nov. placed therein', by Balish M., et al. (Int J Syst Evol Microbiol, 2019;69:3650-3653). Int J Syst Evol Microbiol. 2020;70(2):1431-1438. DOI: 10.1099/ijsem.0.003869

3. Gupta R.S., Sawnani S., Adeolu M., Alnajar S., Oren A. Phylogenetic framework for the phylum Tenericutes based on genome sequence data: proposal for the creation of a new order Mycoplasmoidales ord. nov., containing two new families Mycoplasmoidaceae fam. nov. and Metamycoplasmataceae fam. nov. harbouring Eperythrozoon, Ureaplasma and five novel genera. Antonie Van Leeuwenhoek. 2018;111(9):1583-1630. DOI: 10.1007/s10482-018-1047-3

4. Hu J., Ye Y., Chen X., Xiong L., Xie W., Liu P. Insight into the pathogenic mechanism of Mycoplasma pneumoniae. Curr Microbiol. 2023;80(1):14. DOI: 10.1007/s00284-022-03103-0

5. Charon N.W. Mycoplasma takes a walk. Proc Natl Acad Sci. 2005;102(39):13713-13714. DOI: 10.1073/pnas.0506508102

6. Atkinson T.P., Balish M.F., Waites K.B. Epidemiology, clinical manifestations, pathogenesis and laboratory detection of Mycoplasma pneumoniae infections. FEMS Microbiol Rev. 2008;32(6):956-973. DOI: 10.1111/j.1574-6976.2008.00129.x

7. Himmelreich R., Hilbert H., Plagens H., Pirkl E., Li B.C., Herrmann R. Complete sequence analysis of the genome of the bacterium Mycoplasma pneumoniae. Nucleic Acids Res. 1996;24(22):4420-4449. DOI: 10.1093/nar/24.22.4420

8. Rudd K.E. EcoGene: a genome sequence database for Escherichia coli K-12. Nucleic Acids Res. 2000;28(1):60-64. DOI: 10.1093/nar/28.1.60

9. Dandekar T., Snel B., Schmidt S., Lathe W., Suyama M., Huynen M., Bork P. Comparative genome analysis of the Mollicutes. In: Molecular Biology and Pathogenicity of Mycoplasmas. Springer US; 2002:255-278. DOI: 10.1007/0-306-47606-1_11

10. Pollack J.D., Myers M.A., Dandekar T., Herrmann R. Suspected utility of enzymes with multiple activities in the small genome Mycoplasma species: the replacement of the missing “household” nucleoside diphosphate kinase gene and activity by glycolytic kinases. Omi A J Integr Biol. 2002;6(3):247-258. DOI: 10.1089/15362310260256909

11. Pereyre S., Goret J., Bébéar C. Mycoplasma pneumoniae: current knowledge on macrolide resistance and treatment. Front Microbiol. 2016;7:974. DOI: 10.3389/fmicb.2016.00974

12. Wernegreen J.J. For better or worse: genomic consequences of intracellular mutualism and parasitism. Curr Opin Genet Dev. 2005;15(6):572-583. DOI: 10.1016/j.gde.2005.09.013

13. Talkington D.F., Schwartz S.B., Besser R.E., Waites K.B. Emerging from obscurity: understanding pulmonary and extrapulmonary syndromes, pathogenesis, and epidemiology of human Mycoplasma pneumoniae infections. In: Emerging Infections 5. American Society of Microbiology. 2001. DOI: 10.1128/9781555816988.ch4

14. Rottem S. Interaction of mycoplasmas with host cells. Physiol Rev. 2003;83(2):417-432. DOI: 10.1152/physrev.00030.2002

15. Balish M.F. Subcellular structures of mycoplasmas. Front Biosci. 2006;11(1):2017. DOI: 10.2741/1943

16. Balish M.F., Krause D.C. Mycoplasmas: a distinct cytoskeleton for wall-less bacteria. J Mol Microbiol Biotechnol. 2006;11(3-5):244-255. DOI: 10.1159/000094058

17. Henderson G.P., Jensen G.J. Three-dimensional structure of Mycoplasma pneumoniae’s attachment organelle and a model for its role in gliding motility. Mol Microbiol. 2006;60(2):376-385. DOI: 10.1111/j.1365-2958.2006.05113.x

18. Seybert A., Herrmann R., Frangakis A.S. Structural analysis of Mycoplasma pneumoniae by cryo-electron tomography. J Struct Biol. 2006;156(2):342-354. DOI: 10.1016/j.jsb.2006.04.010

19. Nakane D., Adan-Kubo J., Kenri T., Miyata M. Isolation and characterization of P1 adhesin, a leg protein of the gliding bacterium Mycoplasma pneumoniae. J Bacteriol. 2011;193(3):715-722. DOI: 10.1128/JB.00796-10

20. Layh-Schmitt G., Herrmann R. Localization and biochemical characterization of the ORF6 gene product of the Mycoplasma pneumoniae P1 operon. Infect Immun. 1992;60(7):2906-2913. DOI: 10.1128/iai.60.7.2906-2913.1992

21. Nakane D., Kenri T., Matsuo L., Miyata M. Systematic structural analyses of attachment organelle in Mycoplasma pneumoniae. PLoS Pathog. 2015;11(12):e1005299. DOI: 10.1371/journal.ppat.1005299

22. Boonmee A., Ruppert T., Herrmann R. The gene mpn310 (hmw2) from Mycoplasma pneumoniae encodes two proteins, HMW2 and HMW2-s, which differ in size but use the same reading frame. FEMS Microbiol Lett. 2008;290(2):174-181. DOI: 10.1111/j.1574-6968.2008.01422.x

23. Hasselbring B.M., Jordan J.L., Krause D.C. Mutant analysis reveals a specific requirement for protein P30 in Mycoplasma pneumoniae gliding motility. J Bacteriol. 2005;187(18):6281-6289. DOI: 10.1128/JB.187.18.6281-6289.2005

24. Gray G.C., Duffy L.B., Paver R.J., Putnam S.D., Reynolds R.J., Cassell G.H. Mycoplasma pneumoniae: a frequent cause of pneumonia among U.S. Marines in southern California. Mil Med. 1997;162(8):524-526. PMID: 9271902.

25. Jordan J.L., Chang H.Y., Balish M.F., Holt L.S., Bose S.R., Hasselbring B.M., et al. Protein P200 is dispensable for Mycoplasma pneumoniae hemadsorption but not gliding motility or colonization of differentiated bronchial epithelium. Infect Immun. 2007;75(1):518-522. DOI: 10.1128/IAI.01344-06

26. Hegermann J., Herrmann R., Mayer F. Cytoskeletal elements in the bacterium Mycoplasma pneumoniae. Naturwissenschaften. 2002;89(10):453-458. DOI: 10.1007/s00114-002-0359-2

27. Hatchel J.M., Balish M.F. Attachment organelle ultrastructure correlates with phylogeny, not gliding motility properties, in Mycoplasma pneumoniae relatives. Microbiology. 2008;154(1):286-295. DOI: 10.1099/mic.0.2007/012765-0

28. Seto S., Kenri T., Tomiyama T., Miyata M. Involvement of P1 adhesin in gliding motility of Mycoplasma pneumoniae as revealed by the inhibitory effects of antibody under optimized gliding conditions. J Bacteriol. 2005;187(5):1875-1877. DOI: 10.1128/JB.187.5.1875-1877.2005

29. Vilei E.M., Frey J. Genetic and biochemical characterization of glycerol uptake in Mycoplasma mycoides subsp. mycoides SC: its impact on H2O2 production and virulence. Clin Vaccine Immunol. 2001;8(1):85-92. DOI: 10.1128/CDLI.8.1.85-92.2001

30. Pilo P., Vilei E.M., Peterhans E., Bonvin-Klotz L., Stoffel M.H., Dobbelaere D., Frey J. A metabolic enzyme as a primary virulence factor of Mycoplasma mycoides subsp. mycoides small colony. J Bacteriol. 2005;187(19):6824-6831. DOI: 10.1128/JB.187.19.6824-6831.2005

31. Low I.E. Effect of medium on H(2)O(2) levels and peroxidase-like activity by Mycoplasma pneumoniae. Infect Immun. 1971;3(1):80-86. DOI: 10.1128/iai.3.1.80-86.1971

32. Galinier A., Kravanja M., Engelmann R., Hengstenberg W., Kilhoffer M.C., Deutscher J., Haiech J. New protein kinase and protein phosphatase families mediate signal transduction in bacterial catabolite repression. Proc Natl Acad Sci. 1998;95(4):1823-1828. DOI: 10.1073/pnas.95.4.1823

33. Merzbacher M., Detsch C., Hillen W., Stulke J. Mycoplasma pneumoniae HPr kinase/phosphorylase. Assigning functional roles to the P-loop and the HPr kinase/phosphorylase signature sequence motif. Eur J Biochem. 2004;271(2):367-374. DOI: 10.1046/j.1432-1033.2003.03935.x

34. Almagor M., Kahane I., Yatziv S. Role of superoxide anion in host cell injury induced by Mycoplasma pneumoniae infection. A study in normal and trisomy 21 cells. J Clin Invest. 1984;73(3):842-847. DOI: 10.1172/JCI111279

35. Tryon V.V, Baseman J.B. The acquisition of human lactoferrin by Mycoplasma pneumoniae. Microb Pathog. 1987;3(6):437-443. DOI: 10.1016/0882-4010(87)90013-1

36. Yang J., Hooper W.C., Phillips D.J., Talkington D.F. Regulation of proinflammatory cytokines in human lung epithelial cells infected with Mycoplasma pneumoniae. Infect Immun. 2002;70(7):3649-3655. DOI: 10.1128/IAI.70.7.3649-3655.2002

37. Collier A.M., Baseman J.B. Organ culture techniques with mycoplasmas. Ann N Y Acad Sci. 1973;225(1):277-289. DOI: 10.1111/j.1749-6632.1973.tb45656.x

38. Waites K.B., Simecka J.W., Talkington D.F., Atkinson T.P. Pathogenesis of Mycoplasma pneumoniae infections:adaptive immunity, innate immunity, cell biology, and virulence factors. In: Community-Acquired Pneumonia. Birkhäuser Basel. 2007. DOI: 10.1007/978-3-7643-7563-8_9

39. Kannan T.R., Baseman J.B. ADP-ribosylating and vacuolating cytotoxin of Mycoplasma pneumoniae represents unique virulence determinant among bacterial pathogens. Proc Natl Acad Sci. 2006;103(17):6724-6729. DOI: 10.1073/pnas.0510644103

40. Becker A., Kannan T.R., Taylor A.B., Pakhomova O.N., Zhang Y., Somarajan S.R., et al. Structure of CARDS toxin, a unique ADP-ribosylating and vacuolating cytotoxin from Mycoplasma pneumoniae. Proc Natl Acad Sci. 2015;112(16):5165-5170. DOI: 10.1073/pnas.1420308112

41. Hardy R.D., Coalson J.J., Peters J., Chaparro A., Techasaensiri C., Cantwell A.M., et al. Analysis of pulmonary inflammation and function in the mouse and baboon after exposure to Mycoplasma pneumoniae CARDS toxin. PLoS One. 2009;4(10):e7562. DOI: 10.1371/journal.pone.0007562

42. Medina J.L., Coalson J.J., Brooks E.G., Le Saux C.J., Winter V.T., Chaparro A., et al. Mycoplasma pneumoniae CARDS toxin exacerbates ovalbumin-induced asthma-like inflammation in BALB/c mice. PLoS One. 2014;9(7):e102613. DOI: 10.1371/journal.pone.0102613

43. Techasaensiri C., Tagliabue C., Cagle M., Iranpour P., Katz K., Kannan T.R., et al. Variation in colonization, ADP-ribosylating and vacuolating cytotoxin, and pulmonary disease severity among Mycoplasma pneumoniae strains. Am J Respir Crit Care Med. 2010;182(6):797-804. DOI: 10.1164/rccm.201001-0080OC

44. Johnson C., Kannan T.R., Baseman J.B. Cellular vacuoles induced by Mycoplasma pneumoniae CARDS toxin originate from Rab9-associated compartments. PLoS One. 2011;6(7):e22877. DOI: 10.1371/journal.pone.0022877

45. Bose S., Segovia J. A., Somarajan S. R., Chang T. H., Kannan T. R., Baseman J.B. ADP-ribosylation of NLRP3 by Mycoplasma pneumoniae CARDS toxin regulates inflammasome activity. MBio. 2014;5(6):e02186-14. DOI: 10.1128/mBio.02186-14

46. Im H., Ammit A.J. The NLRP3 inflammasome: role in airway inflammation. Clin Exp Allergy. 2014;44(2):160-172. DOI: 10.1111/cea.12206

47. Kannan T.R., Musatovova O., Balasubramanian S., Cagle M., Jordan J.L., Krunkosky T.M., et al. Mycoplasma pneumoniae community acquired respiratory distress syndrome toxin expression reveals growth phase and infection-dependent regulation. Mol Microbiol. 2010;76(5):1127-1141. DOI: 10.1111/j.1365-2958.2010.07092.x

48. Somarajan S. R., Al-Asadi F., Ramasamy K., Pandranki L., Baseman J.B., Kannan T.R. Annexin A2 mediates Mycoplasma pneumoniae community-acquired respiratory distress syndrome toxin binding to eukaryotic cells. MBio. 2014;5(4). DOI: 10.1128/mBio.01497-14

49. Waites K.B., Talkington D.F. Mycoplasma pneumoniae and its role as a human pathogen. Clin Microbiol Rev. 2004;17(4):697-728. DOI: 10.1128/CMR.17.4.697-728.2004

50. Wilson M.H., Collier A.M. Ultrastructural study of Mycoplasma pneumoniae in organ culture. J Bacteriol. 1976;125(1):332-339. DOI: 10.1128/jb.125.1.332-339.1976

51. Polkowska A., Harjunpää A., Toikkanen S., Lappalainen M., Vuento R., Vuorinen T., et al. Increased incidence of Mycoplasma pneumoniae infection in Finland, 2010-2011. Euro Surveill. 2012;17(5):20072. DOI: 10.2807/ese.17.05.20072-en

52. Bébéar C., Pereyre S., Peuchant O. Mycoplasma pneumoniae: susceptibility and resistance to antibiotics. Future Microbiol. 2011;6(4):423-431. DOI: 10.2217/fmb.11.18

53. Higgins R.R., Lombos E., Tang P., Rohoman K., Maki A., Brown S., et al. Verification of the ProPneumo-1 assay for the simultaneous detection of Mycoplasma pneumoniae and Chlamydophila pneumoniae in clinical respiratory specimens. Ann Clin Microbiol Antimicrob. 2009;8(1):10. DOI: 10.1186/1476-0711-8-10

54. Jacobs E., Ehrhardt I., Dumke R. New insights in the outbreak pattern of Mycoplasma pneumoniae. Int J Med Microbiol. 2015;305(7):705-708. DOI: 10.1016/j.ijmm.2015.08.021

55. Loens K., Goossens H., Ieven M. Acute respiratory infection due to Mycoplasma pneumoniae: current status of diagnostic methods. Eur J Clin Microbiol Infect Dis. 2010;29(9):1055-1069. DOI: 10.1007/s10096-010-0975-2

56. Kannan T.R., Hardy R.D., Coalson J.J., Cavuoti D.C., Siegel J.D., Cagle M., et al. Fatal outcomes in family transmission of Mycoplasma pneumoniae. Clin Infect Dis. 2012;54(2):225-231. DOI: 10.1093/cid/cir769

57. Dorigo‐Zetsma J.W., Wilbrink B., van der Nat H., Bartelds A.I. M., Heijnen M.A., Dankert J. Results of molecular detection of Mycoplasma pneumoniae among patients with acute respiratory infection and in their household contacts reveals children as human reservoirs. J Infect Dis. 2001;183(4):675-678. DOI: 10.1086/318529

58. Ferwerda A., Moll H.A., de Groot R. Respiratory tract infections by Mycoplasma pneumoniae in children: a review of diagnostic and therapeutic measures. Eur J Pediatr. 2001;160(8):483-491. DOI: 10.1007/s004310100775

59. Muldoon R. L., Raucci J., Kowalski J., Rajashekaraiah K. An outbreak of Mycoplasma pneumoniae respiratory illness in a semi-closed religious commune. Ann Emerg Med. 1982;11(11):613-615. DOI: 10.1016/S0196-0644(82)80203-5

60. Leibowitz Z., Schvartzman P., Epstein L., Lis I., Naot Y. An outbreak of Mycoplasma pneumoniae pneumonia in two kibbutzim: a clinical and epidemiologic study. Isr J Med Sci. 1988;24(2):88-92. PMID: 3356539.

61. Feikin D. R., Moroney J. F., Talkington D. F., Thacker W.L., Code J.E., Schwartz L.A., et al. An outbreak of acute respiratory disease caused by Mycoplasma pneumoniae and adenovirus at a federal service training academy: new implications from an old scenario. Clin Infect Dis. 1999;29(6):1545-1550. DOI: 10.1086/313500

62. Gray G.C., Callahan J.D., Hawksworth A.W., Fisher C.A., Gaydos J.C. Respiratory diseases among U.S. military personnel: countering emerging threats. Emerg Infect Dis. 1999;5(3):379-387. DOI: 10.3201/eid0503.990308

63. Mogabgab W.J. Mycoplasma pneumoniae and adenovirus respiratory illnesses in military and university personnel, 1959-1966. Am Rev Respir Dis. 1968;97(3):345-358. DOI: 10.1164/arrd.1968.97.3.345

64. Edwards E.A., Crawford Y.E., Pierce W.E., Peckinpaugh R.O. A longitudinal study of Mycoplasma pneumoniae: infections in navy recruits by isolation and seroepidemiology. Am J Epidemiol. 1976;104(5):556-562. DOI: 10.1093/oxfordjournals.aje.a112330

65. Kleemola M., Jokinen C. Outbreak of Mycoplasma pneumoniae infection among hospital personnel studied by a nucleic acid hybridization test. J Hosp Infect. 1992;21(3):213-221. DOI: 10.1016/0195-6701(92)90078-Z

66. Fischman R.A., Marschall K.E., Kislak J.W., Greenbaum D.M. Adult respiratory distress syndrome caused by Mycoplasma pneumoniae. Chest. 1978;74(4):471. DOI: 10.1378/chest.74.4.471

67. Gray G.C., Mitchell B.S., Tueller J.E., Cross E.R., Amundson D.E. Pneumonia hospitalizations in the US navy and marine corps: rates and risk factors for 6,522 admissions, 1981-1991. Am J Epidemiol. 1994;139(8):793-802. DOI: 10.1093/oxfordjournals.aje.a117076

68. Alexander E.R., Foy H.M., Kenny G.E., Kronmal R.A., McMahan R., Clarke E.R., et al. Pneumonia due to Mycoplasma pneumoniae. N Engl J Med. 1966;275(3):131-136. DOI: 10.1056/NEJM196607212750303

69. Wubbel L., Muniz L., Ahmed A., Trujillo M., Carubelli C., McCoig C., et al. Etiology and treatment of communityacquired pneumonia in ambulatory children. Pediatr Infect Dis J. 1999;18(2):98-104. DOI: 10.1097/00006454-199902000-00004

70. Luby J.P. Pneumonia caused by Mycoplasma pneumoniae infection. Clin Chest Med. 1991;12(2):237-244. PMID: 1906790.

71. Harris J.A.S., Kolokathis A., Campbell M., Cassell G.H., Hammerschlag M. R. Safety and efficacy of azithromycin in the treatment of community-acquired pneumonia in children. Pediatr Infect Dis J. 1998;17(10):865-871. DOI: 10.1097/00006454-199810000-00004

72. Heiskanen-Kosma T., Korppi M., Jokinen C., Kurki S., Heiskanen L., Juvonen H., et al. Etiology of childhood pneumonia: serologic results of a prospective, populationbased study. Pediatr Infect Dis J. 1998;17(11):986-991. DOI: 10.1097/00006454-199811000-00004

73. Foy H.M. Infections caused by Mycoplasma pneumoniae and possible carrier state in different populations of patients. Clin Infect Dis. 1993;17(Suppl. 1):S37-S46. DOI: 10.1093/clinids/17.Supplement_1.S37

74. Block S., Hedrick J., Hammersclag M.R., Cassell G.H., Craft J.C. Mycoplasma pneumoniae and Chlamydia pneumoniae in pediatric community-acquired pneumonia. Pediatr Infect Dis J. 1995;14(6):471-477. DOI: 10.1097/00006454-199506000-00002

75. Spuesens E.B.M., Oduber M., Hoogenboezem T., Sluijter M., Hartwig N.G., van Rossum A.M.C., Vink C. Sequence variations in RepMP2/3 and RepMP4 elements reveal intragenomic homologous DNA recombination events in Mycoplasma pneumoniae. Microbiology. 2009;155(7):2182-2196. DOI: 10.1099/mic.0.028506-0

76. Dumke R., Catrein I., Herrmann R., Jacobs E. Preference, adaptation and survival of Mycoplasma pneumoniae subtypes in an animal model. Int J Med Microbiol. 2004;294(2-3):149-155. DOI: 10.1016/j.ijmm.2004.06.020

77. Zhao F., Liu L., Tao X., He L., Meng F., Zhang J. CultureIndependent Detection and genotyping of Mycoplasma pneumoniae in clinical specimens from Beijing, China. PLoS One. 2015;10(10):e0141702. DOI: 10.1371/journal.pone.0141702

78. Kenri T., Okazaki N., Yamazaki T., Narita M., Izumikawa K., Matsuoka M., et al. Genotyping analysis of Mycoplasma pneumoniae clinical strains in Japan between 1995 and 2005: type shift phenomenon of M. pneumoniae clinical strains. J Med Microbiol. 2008;57(4):469-475. DOI: 10.1099/jmm.0.47634-0

79. Schwartz S.B., Thurman K.A., Mitchell S.L., Wolff B.J., Winchell J.M. Genotyping of Mycoplasma pneumoniae isolates using real-time PCR and high-resolution melt analysis. Clin Microbiol Infect. 2009;15(8):756-762. DOI: 10.1111/j.1469-0691.2009.02814.x

80. Martinez M.A., Ruiz M., Zunino E., Luchsinger V., Aguirre R., Avendano L. F. Identification of P1 types and variants of Mycoplasma pneumoniae during an epidemic in Chile. J Med Microbiol. 2010;59(8):925-929. DOI: 10.1099/jmm.0.018333-0

81. Nilsson A.C., Björkman P., Welinder-Olsson C., Widell A., Persson K. Clinical severity of Mycoplasma pneumoniae (MP) infection is associated with bacterial load in oropharyngeal secretions but not with MP genotype. BMC Infect Dis. 2010;10(1):39. DOI: 10.1186/1471-2334-10-39

82. Diaz M.H., Benitez A.J., Winchell J.M. Investigations of Mycoplasma pneumoniae infections in the United States: trends in molecular typing and macrolide resistance from 2006 to 2013. J Clin Microbiol. 2015;53(1):124-130. DOI: 10.1128/JCM.02597-14

83. Uldum S.A., Bangsborg J.M., Gahrn-Hansen B., Ljung R., Mølvadgaard M., Føns Petersen R., et al. Epidemic of Mycoplasma pneumoniae infection in Denmark, 2010 and 2011. Euro Surveill. 2012;17(5):20073. DOI: 10.2807/ese.17.05.20073-en

84. Chalker V.J., Stocki T., Mentasti M., Fleming D., Sadler C., Ellis J., et al. Mycoplasma pneumoniae infection in primary care investigated by real-time PCR in England and Wales. Eur J Clin Microbiol Infect Dis. 2011;30(7):915-921. DOI: 10.1007/s10096-011-1176-3

85. Linde A., Ternhag A., Torner A., Claesson B. Antibiotic prescriptions and laboratory-confirmed cases of Mycoplasma pneumoniae during the epidemic in Sweden in 2011. Euro Surveill. 2012;17(6):20082. PMID: 22340974.

86. Blystad H., Ånestad G., Vestrheim D.F., Madsen S., Rønning K. Increased incidence of Mycoplasma pneumoniae infection in Norway 2011. Euro Surveill. 2012;17(5). DOI: 10.2807/ese.17.05.20074-en

87. Okada T., Morozumi M., Tajima T., Hasegawa M., Sakata H., Ohnari S., et al. Rapid effectiveness of minocycline or doxycycline against macrolide-resistant Mycoplasma pneumoniae infection in a 2011 outbreak among japanese children. Clin Infect Dis. 2012;55(12):1642-1649. DOI: 10.1093/cid/cis784

88. Qu J., Yu X., Liu Y., Yin Y., Gu L., Cao B., Wang C. Specific multilocus variable-number tandem-repeat analysis genotypes of Mycoplasma pneumoniae are associated with diseases severity and macrolide susceptibility. PLoS One. 2013;8(12):e82174. DOI: 10.1371/journal.pone.0082174

89. Kim E.K., Youn Y.S., Rhim J.W., Shin M.S., Kang J.H., Lee K.Y. Epidemiological comparison of three Mycoplasma pneumoniae pneumonia epidemics in a single hospital over 10 years. Korean J Pediatr. 2015;58(5):172. DOI: 10.3345/kjp.2015.58.5.172

90. Pereyre S., Charron A., Hidalgo-Grass C., Touati A., Moses A.E., Nir-Paz R., Bébéar C. The spread of Mycoplasma pneumoniae is polyclonal in both an endemic setting in France and in an epidemic setting in Israel. PLoS One. 2012;7(6):e38585. DOI: 10.1371/journal.pone.0038585

91. Nir-Paz R., Abutbul A., Moses A.E., Block C., HidalgoGrass C. Ongoing epidemic of Mycoplasma pneumoniae infection in Jerusalem, Israel, 2010 to 2012. Euro Surveill. 2012;17(8):20095. PMID: 22401504.

92. Edelstein I., Rachina S., Touati A., Kozlov R., Henin N., Bébéar C., Pereyre S. Mycoplasma pneumoniae monoclonal P1 type 2c outbreak, Russia, 2013. Emerg Infect Dis. 2016;22(2):348-350. DOI: 10.3201/eid2202.151349

93. Spuesens E.B.M, Fraaij P.L.A., Visser E.G., Hoogenboezem T., Hop W.C., van Adrichem L.N., et al. Carriage of Mycoplasma pneumoniae in the upper respiratory tract of symptomatic and asymptomatic children: an observational study. PLoS Med. 2013;10(5):e1001444. DOI: 10.1371/journal.pmed.1001444

94. Wood P.R., Hill V.L., Burks M.L., Peters J.I., Singh H., Kannan T.R., et al. Mycoplasma pneumoniae in children with acute and refractory asthma. Ann Allergy Asthma Immunol. 2013;110(5):328-334.e1. DOI: 10.1016/j.anai.2013.01.022

95. Centor R.M., Atkinson T.P., Ratliff A.E., Xiao L., Crabb D.M., Estrada C.A., et al. The clinical presentation of Fusobacterium-positive and streptococcal-positive pharyngitis in a university health clinic. Ann Intern Med. 2015;162(4):241. DOI: 10.7326/M14-1305

96. Vervloet L.A., Marguet C., Camargos P.A.M. Infection by Mycoplasma pneumoniae and its importance as an etiological agent in childhood community-acquired pneumonias. Brazilian J Infect Dis. 2007;11(5):507-514. DOI: 10.1590/S1413-86702007000500012

97. Koletsky R.J., Weinstein A.J. Fulminant Mycoplasma pneumoniae infection. Report of a fatal case, and a review of the literature. Am Rev Respir Dis. 1980;122(3):491-496. DOI: 10.1164/arrd.1980.122.3.491

98. Chan E.D., Welsh C.H. Fulminant Mycoplasma pneumoniae pneumonia. West J Med. 1995;162(2):133-142. PMID: 7725685.

99. Park S.J., Pai K.S., Kim A.R., Lee J.H., Shin J.I., Lee S.Y. Fulminant and fatal multiple organ failure in a 12-yearold boy with Mycoplasma pneumoniae infection. Allergy Asthma Immunol Res. 2012;4(1):55-57. DOI: 10.4168/aair.2012.4.1.55

100. Izumikawa K., Izumikawa K., Takazono T., Kosai K., Morinaga Y., Nakamura S., et al. Clinical features, risk factors and treatment of fulminant Mycoplasma pneumoniae pneumonia: a review of the Japanese literature. J Infect Chemother. 2014;20(3):181-185. DOI: 10.1016/j.jiac.2013.09.009

101. Waites K.B., Xiao L., Liu Y., Balish M.F., Atkinson T.P. Mycoplasma pneumoniae from the respiratory tract and beyond. Clin Microbiol Rev. 2017;30(3):747-809. DOI: 10.1128/CMR.00114-16

102. Miyashita N., Akaike H., Teranishi H., Nakano T., Ouchi K., Okimoto N. Chest computed tomography for the diagnosis of Mycoplasma pneumoniae infection. Respirology. 2014;19(1):144-145. DOI: 10.1111/resp.12218

103. Leonardi S., Pavone P., Rotolo N., La Rosa M. Stroke in two children with Mycoplasma pneumoniae infection a causal or casual relationship? Pediatr Infect Dis J. 2005;24(9):843-845. DOI: 10.1097/01.inf.0000177284.88356.56

104. Guleria R., Nisar N., Chawla T.C., Biswas N.R. Mycoplasma pneumoniae and central nervous system complications: a review. J Lab Clin Med. 2005;146(2):55-63. DOI: 10.1016/j.lab.2005.04.006

105. Meyer Sauteur P.M., Moeller A., Relly C., Berger C., Plecko B., Nadal D.; Swiss Pediatric Surveillance Unit (SPSU). Swiss national prospective surveillance of paediatric Mycoplasma pneumoniae-associated encephalitis. Swiss Med Wkly. 2016 Jan 11:146:w14222. DOI: 10.4414/smw.2016.14222

106. Kammer J., Ziesing S., Davila L., Bültmann E., Illsinger S., Das A.M., et al. Neurological manifestations of Mycoplasma pneumoniae infection in hospitalized children and their long-term follow-up. Neuropediatrics. 2016;47(05):308-317. DOI: 10.1055/s-0036-1584325

107. Narita M. Pathogenesis of neurologic manifestations of Mycoplasma pneumoniae infection. Pediatr Neurol. 2009;41(3):159-166. DOI: 10.1016/j.pediatrneurol.2009.04.012

108. Tsiodras S., Kelesidis I., Kelesidis T., Stamboulis E., Giamarellou H. Central nervous system manifestations of Mycoplasma pneumoniae infections. J Infect. 2005; 51(5):343-354. DOI: 10.1016/j.jinf.2005.07.005

109. Sánchez-Vargas F.M., Gómez-Duarte O.G. Mycoplasma pneumoniae – an emerging extra-pulmonary pathogen. Clin Microbiol Infect. 2008;14(2):105-115. DOI: 10.1111/j.1469-0691.2007.01834.x

110. Tay Y.K., Huff J.C., Weston W.L. Mycoplasma pneumoniae infection is associated with Stevens-Johnson syndrome, not erythema multiforme (von Hebra). J Am Acad Dermatol. 1996;35(5):757-760. DOI: 10.1016/S0190-9622(96)90732-X

111. Latsch K., Girschick H.J., Abele-Horn M. Stevens Johnson syndrome without skin lesions. J Med Microbiol. 2007;56(12):1696-1699. DOI: 10.1099/jmm.0.47318-0

112. Narita M. Pathogenesis of extrapulmonary manifestations of Mycoplasma pneumoniae infection with special reference to pneumonia. J Infect Chemother. 2010;16(3):162-169. DOI: 10.1007/s10156-010-0044-X

113. Oishi T., Narita M., Ohya H., Yamanaka T., Aizawa Y., Matsuo M., et al. Rhabdomyolysis associated with antimicrobial drug-resistant Mycoplasma pneumoniae. Emerg Infect Dis. 2012;18(5):849-851. DOI: 10.3201/eid1805.111149

114. Weng W.C., Peng S.S.F., Wang S.B., Chou Y.T., Lee W.T. Mycoplasma pneumoniae-associated transverse myelitis and rhabdomyolysis. Pediatr Neurol. 2009;40(2):128-130. DOI: 10.1016/j.pediatrneurol.2008.10.009

115. Jayantha U. Mycoplasma pneumoniae infection in Sri Lanka. Sri Lanka J Child Heal. 2008;36(2):43. DOI: 10.4038/sljch.v36i2.48

116. Nisar N., Guleria R., Kumar S., Chand Chawla T., Ranjan Biswas N. Mycoplasma pneumoniae and its role in asthma. Postgrad Med J. 2007;83(976):100-104. DOI: 10.1136/pgmj.2006.049023

117. Kraft M., Cassell G.H., Pak J., Martin R.J. Mycoplasma pneumoniae and Chlamydia pneumoniae in asthma. Chest. 2002;121(6):1782-1788. DOI: 10.1378/chest.121.6.1782

118. Martin R.J., Kraft M., Chu H.W., Berns E.A., Cassell G.H. A link between chronic asthma and chronic infection. J Allergy Clin Immunol. 2001;107(4):595-601. DOI: 10.1067/mai.2001.113563

119. Biscardi S., Lorrot M., Marc E., Moulin F., Boutonnat-Faucher B., Heilbronner C., et al. Mycoplasma pneumoniae and asthma in children. Clin Infect Dis. 2004;38(10):1341-1346. DOI: 10.1086/392498

120. Lieberman D., Lieberman D., Printz S., Ben-Yaakov M., Lazarovich Z., Ohana B., et al. Atypical pathogen infection in adults with acute exacerbation of bronchial asthma. Am J Respir Crit Care Med. 2003;167(3):406-410. DOI: 10.1164/rccm.200209-996OC

121. Nir-Paz R., Michael-Gayego A., Ron M., Block C. Evaluation of eight commercial tests for Mycoplasma pneumoniae antibodies in the absence of acute infection. Clin Microbiol Infect. 2006;12(7):685-688. DOI: 10.1111/j.1469-0691.2006.01469.x

122. Atkinson T.P., Waites K.B. Mycoplasma pneumoniae infections in childhood. Pediatr Infect Dis J. 2014;33(1):92-94. DOI: 10.1097/INF.0000000000000171

123. Thacker W.L., Talkington D.F. Analysis of complement fixation and commercial enzyme immunoassays for detection of antibodies to Mycoplasma pneumoniae in human serum. Clin Vaccine Immunol. 2000;7(5):778-780. DOI: 10.1128/CDLI.7.5.778-780.2000

124. Waites K.B., Xiao L., Paralanov V., Viscardi R.M., Glass J.I. Molecular methods for the detection of Mycoplasma and Ureaplasma infections in humans: a paper from the 2011 William Beaumont Hospital Symposium on molecular pathology. J Mol Diagn. 2012;14(5):437-450. DOI: 10.1016/j.jmoldx.2012.06.001

125. Diaz M.H., Winchell J.M. The evolution of advanced molecular diagnostics for the detection and characterization of Mycoplasma pneumoniae. Front Microbiol. 2016;7:232. DOI: 10.3389/fmicb.2016.00232

126. Ieven M., Loens K. Should serology be abolished in favor of PCR for the diagnosis of Mycoplasma pneumoniae infections? Curr Pediatr Rev. 2013;9(4):304-313. DOI: 10.2174/157339630904131223110501

127. Loens K., Ieven M. Mycoplasma pneumoniae: current knowledge on nucleic acid amplification techniques and serological diagnostics. Front Microbiol. 2016;7:448. DOI: 10.3389/fmicb.2016.00448

128. Saito R. Development and evaluation of a loopmediated isothermal amplification assay for rapid detection of Mycoplasma pneumoniae. J Med Microbiol. 2005;54(11):1037-1041. DOI: 10.1099/jmm.0.46071-0

129. Pitcher D. Real-time detection of Mycoplasma pneumoniae in respiratory samples with an internal processing control. J Med Microbiol. 2006;55(2):149-155. DOI: 10.1099/jmm.0.46281-0

130. Loens K., Ursi D., Ieven M., van Aarle P., Sillekens P., Oudshoorn P., Goossens H. Detection of Mycoplasma pneumoniae in spiked clinical samples by nucleic acid sequence-based amplification. J Clin Microbiol. 2002; 40(4):1339-1345. DOI: 10.1128/JCM.40.4.1339-1345.2002

131. Loens K., Ursi D., Goossens H., Ieven M. Molecular Diagnosis of Mycoplasma pneumoniae respiratory tract infections. J Clin Microbiol. 2003;41(11):4915-4923. DOI: 10.1128/JCM.41.11.4915-4923.2003

132. Notomi T. Loop-mediated isothermal amplification of DNA. Nucleic Acids Res. 2000;28(12):e63. DOI: 10.1093/nar/28.12.e63

133. Aizawa Y., Oishi T., Tsukano S., Taguchi T., Saitoh A. Clinical utility of loop-mediated isothermal amplification for rapid diagnosis of Mycoplasma pneumoniae in children. J Med Microbiol. 2014;63(Pt. 2):248-251. DOI: 10.1099/jmm.0.068288-0

134. Ishiguro N., Koseki N., Kaiho M., Kikuta H., Togashi T., Watanabe T., et al. Sensitivity and specificity of a loopmediated isothermal amplification assay for the detection of Mycoplasma pneumoniae from nasopharyngeal swab samples compared with those of real-time PCR. Clin Lab. 2015;61(5-6):603-606. DOI: 10.7754/clin.lab.2014.141016

135. Petrone B.L., Wolff B.J., DeLaney A.A., Diaz M.H., Winchell J.M. Isothermal detection of Mycoplasma pneumoniae directly from respiratory clinical specimens. J Clin Microbiol. 2015;53(9):2970-2976. DOI: 10.1128/JCM.01431-15

136. Kakuya F., Kinebuchi T., Fujiyasu H., Tanaka R., Kano H. Genetic point-of-care diagnosis of Mycoplasma pneumoniae infection using LAMP assay. Pediatr Int. 2014;56(4):547-552. DOI: 10.1111/ped.12327

137. Gotoh K., Nishimura N., Ohshima Y., Arakawa Y., Hosono H., Yamamoto Y., et al. Detection of Mycoplasma pneumoniae by loop-mediated isothermal amplification (LAMP) assay and serology in pediatric community-acquired pneumonia. J Infect Chemother. 2012;18(5):662-667. DOI: 10.1007/s10156-012-0388-5

138. Ratliff A.E., Duffy L.B., Waites K.B. Comparison of the illumigene Mycoplasma DNA amplification assay and culture for detection of Mycoplasma pneumoniae. J Clin Microbiol. 2014;52(4):1060-1063. DOI: 10.1128/JCM.02913-13

139. Bébéar C.M., Pereyre S. Mechanisms of drug resistance in Mycoplasma pneumoniae. Curr Drug Targets Infect Disord. 2005;5(3):263-271. DOI: 10.2174/1568005054880109

140. Pereyre S., Guyot C., Renaudin H., Charron A., Bebear C., Bebear C.M. In vitro selection and characterization of resistance to macrolides and related antibiotics in Mycoplasma pneumoniae. Antimicrob Agents Chemother. 2004;48(2):460-465. DOI: 10.1128/AAC.48.2.460-465.2004

141. Gruson D., Pereyre S., Renaudin H., Charron A., Bebear C., Bebear C.M. In vitro development of resistance to six and four fluoroquinolones in Mycoplasma pneumoniae and Mycoplasma hominis, respectively. Antimicrob Agents Chemother. 2005;49(3):1190-1193. DOI: 10.1128/AAC.49.3.1190-1193.2005

142. Sainath Rao S., Raghunathan M. In vitro activity of the new quinolone derivative RD-3 against clinical isolates of Mycoplasma pneumoniae and Mycoplasma hominis. J Antimicrob Chemother. 2009;64(6):1336-1338. DOI: 10.1093/jac/dkp375

143. Degrange S., Renaudin H., Charron A., Pereyre S., Bebear C., Bebear C.M. Reduced susceptibility to tetracyclines is associated in vitro with the presence of 16S rRNA mutations in Mycoplasma hominis and Mycoplasma pneumoniae. J Antimicrob Chemother. 2008;61(6):1390-1392. DOI: 10.1093/jac/dkn118

144. Pioletti M. Crystal structures of complexes of the small ribosomal subunit with tetracycline, edeine and IF3. EMBO J. 2001;20(8):1829-1839. DOI: 10.1093/emboj/20.8.1829

145. Pereyre S., Charron A., Renaudin H., Bebear C., Bebear C.M. First report of macrolide-resistant strains and description of a novel nucleotide sequence variation in the P1 adhesin gene in Mycoplasma pneumoniae clinical strains isolated in France over 12 years. J Clin Microbiol. 2007;45(11):3534-3539. DOI: 10.1128/JCM.01345-07

146. Niitu Y., Hasegawa S., Suetake T., Kubota H., Komatsu S., Horikawa M. Resistance of Mycoplasma pneumoniae to erythromycin and other antibiotics. J Pediatr. 1970;76(3):438-443. DOI: 10.1016/S0022-3476(70)80485-1

147. Critchley I.A., Jones M.E., Heinze P.D., Hubbard D., Engler H.D., Evangelista A.T., et al. In vitro activity of levofloxacin against contemporary clinical isolates of Legionella pneumophila, Mycoplasma pneumoniae and Chlamydia pneumoniae from North America and Europe. Clin Microbiol Infect. 2002;8(4):214-221. DOI: 10.1046/j.1469-0691.2002.00392.x.

148. Stopler T., Branski D. Resistance of Mycoplasma pneumoniae to macrolides, lincomycin and streptogramin B. J Antimicrob Chemother. 1986;18(3):359-364. DOI: 10.1093/jac/18.3.359

149. Morozumi M., Iwata S., Hasegawa K., Chiba N., Takayanagi R., Matsubara K., et al. Increased macrolide resistance of Mycoplasma pneumoniae in pediatric patients with community-acquired pneumonia. Antimicrob Agents Chemother. 2008;52(1):348-350. DOI: 10.1128/AAC.00779-07

150. Matsuda K., Narita M., Sera N., Maeda E., Yoshitomi H., Ohya H., et al. Gene and cytokine profile analysis of macrolide-resistant Mycoplasma pneumoniae infection in Fukuoka, Japan. BMC Infect Dis. 2013;13(1):591. DOI: 10.1186/1471-2334-13-591

151. Edelstein I.A., Edelstein M.V., Romanov A.V., Zaitsev A.A., Rakovskaya I.V., Barkhatova O.I., et al. Four cases of resistance mutations in 23S rRNA gene in Mycoplasma pneumoniae isolated fromhospitalized military personnel. Kliniceskaa mikrobiologia i antimikrobnaa himioterapia. 2017;19(3):248-253. Russian.

152. Cao B., Zhao C., Yin Y., Zhao F., Song S.F., Bai L., et al. High prevalence of macrolide resistance in Mycoplasma pneumoniae isolates from adult and adolescent patients with respiratory tract infection in China. Clin Infect Dis. 2010;51(2):189-194. DOI: 10.1086/653535

153. Xin D., Mi Z., Han X., Qin L., Li J., Wei T., et al. Molecular mechanisms of macrolide resistance in clinical isolates of Mycoplasma pneumoniae from China. Antimicrob Agents Chemother. 2009;53(5):2158-2159. DOI: 10.1128/AAC.01563-08

154. Zhao F., Liu G., Wu J., Cao B., Tao X., He L., et al. Surveillance of macrolide-resistant Mycoplasma pneumoniae in Beijing, China, from 2008 to 2012. Antimicrob Agents Chemother. 2013;57(3):1521-1523. DOI: 10.1128/AAC.02060-12

155. Akaike H., Miyashita N., Kubo M., Kawai Y., Tanaka T., Ogita S., et al. In vitro activities of 11 antimicrobial agents against macrolide-resistant Mycoplasma pneumoniae isolates from pediatric patients: results from a multicenter surveillance study. Jpn J Infect Dis. 2012;65(6):535-538. DOI: 10.7883/yoken.65.535

156. Miyashita N., Akaike H., Teranishi H., Ouchi K., Okimoto N. Macrolide-resistant Mycoplasma pneumoniae pneumonia in adolescents and adults: clinical findings, drug susceptibility, and therapeutic efficacy. Antimicrob Agents Chemother. 2013;57(10):5181-5185. DOI: 10.1128/AAC.00737-13

157. Diaz M.H., Benitez A.J., Cross K.E., Hicks L.A., Kutty P., Bramley A.M., et al. Molecular detection and characterization of Mycoplasma pneumoniae among patients hospitalized with community-acquired pneumonia in the United States. Open Forum Infect Dis. 2015; 2(3):ofv106. DOI: 10.1093/ofid/ofv106

158. Cardinale F., Chironna M., Chinellato I., Principi N., Esposito S. Clinical relevance of Mycoplasma pneumoniae macrolide resistance in children. J Clin Microbiol. 2013;51(2):723-724. DOI: 10.1128/JCM.02840-12

159. Wu P.S., Chang L.Y., Lin H.C., Chi H., Hsieh Y.C., Huang Y.C., et al. Epidemiology and clinical manifestations of children with macrolide-resistant Mycoplasma pneumoniae pneumonia in Taiwan. Pediatr Pulmonol. 2013;48(9):904-911. DOI: 10.1002/ppul.22706

160. Matsubara K., Morozumi M., Okada T., Matsushima T., Komiyama O., Shoji M., et al. A comparative clinical study of macrolide-sensitive and macrolide-resistant Mycoplasma pneumoniae infections in pediatric patients. J Infect Chemother. 2009;15(6):380-383. DOI: 10.1007/s10156-009-0715-7

161. Suzuki S., Yamazaki T., Narita M., Okazaki N., Suzuki I., Andoh T., et al. Clinical evaluation of macrolide-resistant Mycoplasma pneumoniae. Antimicrob Agents Chemother. 2006;50(2):709-712. DOI: 10.1128/AAC.50.2.709-712.2006

162. Baseman J.B., Tully J.G. Mycoplasmas: sophisticated, reemerging, and burdened by their notoriety. Emerg Infect Dis. 1997; 3(1):21-32. DOI: 10.3201/eid0301.970103

Mycoplasma pneumoniae – modern data on the structure, molecular biology and epidemiology of the pathogen

Abstract

Views

Shared

Cited by Crossref